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General Summary;
Over the past year, in collaboration with Dr. Danielle Goldwater of
NASA/AMES we have performed spectral analysis of heart rate data from
healthy subjects during weightlessness simulation. The purpose of these
studies was to test the hypothesis that spectral analysis may provide a
sensitive new technique for assessing cardiac function during space
flight and in detecting potentially detrimental effects of certain drugs
on cardiac reserve. The initial findings detailed in the enclosed
reprint and preprints are very promising in this regard.
In particular, the grant has supported the publication of one article
(1), the recent completion of another paper (2) which is being submitted
to the Journal of Applied Physiology and acceptance of an abstract (3)
for presentation at the upcoming 7th International Man in Space
Symposium at NASA Johnson Space Center in February, 1986. Copies of all
these documents have been included. These documents comprise the Final
Technical Report for this Cooperative Agreement.
No patent requests relating to this Cooperative Agreement were
submitted.
Publications:
1. Goldberger AL, Goldwater D, Bhargava V. Atropine unmasks bedrest
deconditioning effect in healthy men: spectral analysis of cardiac
interbeat intervals. Submitted for publication.
2. Goldberger AL, West BJ, Bhargava V. Nonlinear mechanisms in
physiology and pathophysiology. Toward a dynamical theory of health and
disease. Proceedings of the llth International Association for
Mathematics and Computers in Simulation, World Congress, Oslo, 1985.
3. Goldberger AL, Goldwater D, Bhargava V. Atropine unmasks bedrest
deconditioning effect in healthy men. A spectral analysis. (Abst)
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ABSTRACT
Bedrest deconditioning is suspected to reduce cardiac function.
However, quantitation of subtle decreases in cardiac reserve may be
difficult. Normal subjects show considerable variability in heart rate
response, reflected by a relatively broadband interbeat interval power
spectrum. We hypothesized that the deconditioning effects of bedrest
would induce narrowing of this spectrum, reflecting a reduction in the
autonomically-modulated variability in heart rate. Ten aerobically
conditioned men (average 35-50 years) underwent orthostatic tolerance
testing with lower body negative pressure pre-bedrest and after 10 days
of bedrest, while on placebo and after intravenous atropine. Spectra
were derived by Fourier analysis of 128 interbeat interval data sets
from subjects with sufficient numbers of beats during matched periods of
the protocol. Root-mean-square (RMS) values (X±SD) for the band
encompassing the 2nd to 64th harmonics were computed.
Condition Placebo RMS (n=6) Atropine RMS (n=7)
Pre-bedrest
 p=Ng , 93±33 ms p< Q1 r 63±2A ms
Bedrest 84±38 ms A0±23 ms
These data suggest that atropine unmasks the deconditioning effect of
bedrest in athletic men, evidenced by a reduction in interbeat interval
spectral power compared with placebo. Spectral analysis offers a new
means of quantitating the effects of bedrest deconditioning and
autonomic perturbations on cardiac dynamics.
Index words: bedrest deconditioning; autonomic nervous system; power
spectrum analysis; atropine
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INTRODUCTION
The physiological effects of prolonged bedrest are of interest from
two major perspectives. Historically, the deconditioning effects of
bedrest were first studied based on the concern that recumbency itself
might further impair the physiological response to a variety of
unrelated disease states. Thus, to the extent that it adversely
influences adaptive and homeostatic mechanisms, bedrest may actually
both compound the negative effects of the primary disease as well as
retard recovery (7,24). Because it reduces gravitational effects,
bedrest has also been utilized intensively in recent years by
investigators in the manned space program as a way of simulating
weightlessness (21). There has been considerable interest, therefore,
in studying alterations in cardiovascular function as well as in
assessing changes in other physiological processes associated with
"hypodynamic" environments (12).
The major pieces of evidence cited in support of the hypothesis that
bedrest "deconditions" the cardiovascular system are decreased exercise
capacity, increased resting pulse rate and decreased tolerance to
orthostatic stress (3-5,17,20,21,24). The mechanisms underlying these
maladaptive changes, however, are poorly understood. Furthermore, the
likely contribution of changes in autonomic nervous system function has
received limited appraisal. Animal (15) and human (5,16) studies have
suggested altered sympathetic function. The effects of bedrest on
parasympathetic function have not been directly addressed.
A central problem in studying bedrest deconditioning has been the
development of non-invasive yet sensitive tests for assessing overall
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cardiovascular reserve and autonomic function. - Studies of functional
capacity and orthostatic tolerance have been useful in this regard.
A
However, reduced exercise capacity or intolerance to tilt may reflect a
variety of noncardiac changes associated with prolonged bedrest,
including diminished muscular tone and reduced circulating blood volume
(3,17,21,24).
We hypothesized that prolonged bedrest leads to alterations in
autonomic function and that these perturbations will result in a
decrease in the physiologic variability in short-term heart rate
fluctuations. Furthermore, we speculated that such potentially subtle
alterations in neuro-cardiac dynamics might be detected by spectral
(frequency) analysis of cardiac interbeat intervals. In particular, a
reduction in physiological heart-rate variability should be reflected in
a relative narrowing of the interbeat interval power spectrum. This
report describes a novel application of this sensitive technique in
assessing dynamic changes in cardiovascular reserve.
METHODS AND SUBJECTS
Subjects
Ten aerobically-conditioned men ages 35-50 years underwent serial
tests of orthostatic tolerance with lower body negative pressure (LBNP)
performed before, during and after bedrest. All men had a history of
regular aerobic training and a mean maximum oxygen consumption of 47.5
ml kg min. Subjects had to pass a rigorous physical examination which
included treadmill electrocardiogram (ECG), exercise testing and
echocardiography.
Pre-bedrest and Bedrest Protocol
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Subjects were housed in the NASA/Ames Human Research Facility.
During a ten-day pre-bedrest phase the subjects were ambulatory. For
the next ten days, head down (-6°) bedrest was strictly maintained. The
bedrest phase was followed by a two-week ambulatory recovery phase
during which the subjects were allowed to leave the facility for
sedentary activities at home for six days. Subjects returned to live in
the facility for the final week of recovery testing. During the study,
subjects ate a nutritionally balanced diet of 2800 cal/day and drank ad
lib fluids. Caffeine, methyl xanthine-containing beverages, nicotine
and alcohol were prohibited.
Lower Body Negative Pressure (LBNP) Protocol
Subjects were placed in a horizontal cylindrical chamber which
extended from foot to waist level and was sealed at the waist with a
rubber diaphragm. Wall vacuum suction, modulated by a calibrated
regulator and continuously monitored, provided graded orthostatic
stress. The LBNP protocol shown in Fig 1 was employed, consisting of a
5-min control period, 3 min at -30 mm Hg, 5 min each at -50 to -100 mm
Hg in -10 mm Hg increments and a 5 min recovery period following release
of suction. LBNP runs were terminated at signs of syncope or presyncope
evidenced primarily by bradycardia, hypotension or diminution or
reversal of cerebral blood flow which was measured by temporal artery
Doppler flow meter. No subject tolerated the full LBNP protocol through
-100 mm Hg.
The entire protocol beginning with the control period and ending with
recovery will be referred to as a run. Each 5-min period of constant
LBNP, including control and recovery periods, will be referred to as a
stage.
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Drug Interventions- - - - - . . . . .
During the three phases of the study (pre-bedrest, bedrest and
recovery) the subjects were treated with saline placebo, atropine,
phenylephrine and propranolol prior to LBNP as a means of assessing
autonomic function during bedrest. Due to insufficient numbers of data
points for spectral analysis for the phenylephrine and propranolol runs*
only data on placebo and atropine are reported here.
The subjects underwent only one LBNP run per day. Atropine was
administered in a therapeutic dose range of .01 to .02 mg/kg. Subjects
underwent two orientation LBNP exposures with atropine to select the
dosage that would maximize LBNP duration. At a minimum, the dosage of
atropine had to produce a 20% increase in basal heart rate. Once the
dosage was selected during this familiarization phase, the same dosage
was maintained for each subject during pre-bedrest, bedrest and recovery
runs.
The LBNP exposures occurred on days 7,8,9 and 10 of the pre-bedrest
and bedrest study phases. During the recovery phase, the LBNP drug
exposures occurred during the final week.
This protocol was approved by the Ames Human Research Evaluation
Review Board and the subjects gave informed consent to all aspects of
the study prior to entry.
Instrumentation
ECG tracings were obtained from bipolar sternal electrodes using a
Gould analog 9-channel brush recording system. Once per minute, the
chart speed was increased to 100 mm/sec. Parallel channels recorded
vacuum level, blood pressure, and Doppler temporal artery blood flow.
Digital heart rates integrated over 5-sec intervals were obtained with a
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Hewlett-Packard Cardiotachometer. Heart rate measurements for each
subject represent mean values for the five minute period just prior to
each experimental run.
R-R Interval Analysis
R-R intervals were analyzed from portions of the analog data
recorded at 100 mm/sec during each stage of the LBNP protocol. For each
LBNP run, the number of consecutive R-R intervals/run was computed. To
assure an adequate sample size for the Fourier analysis which required
2 data points, we only accepted runs with a minimum of 128 R-R
intervals.
The runs were then paired for intra-subject comparison of the
following four conditions: placebo pre-bedrest vs. placebo recovery
(ambulatory comparison); placebo pre-bedrest vs. placebo bedrest;
atropine pre-bedrest vs. atropine bedrest, and placebo bedrest vs.
atropine pre-bedrest. The same subject did not necessarily have equal
numbers of R-R intervals during identical stages of paired LBNP runs.
Furthermore, each subject did not always achieve the same LBNP stage in
each run. These discrepancies were taken into account by selecting
matched numbers of consecutive R-R intervals from each achieved stage
such that the total number/run was exactly 128. These intervals were
selected by an independent observer according to the following protocol.
1) Only data from equivalent stages were compared. For example if a
subject reached LBNP stage of -60 mm Hg during one run, but only -50 mm
Hg during the paired run, the data from the -60 mm Hg stage was not
utilized in this comparison. 2) The number of R-R intervals in each
stage with LBNP <0 mm Hg was selected to be equal. 3) The combined
number of R-R intervals in the basal and recovery stages (LBNP = 0 mm
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Hg) was selected to be approximately twice the number in each stage with
LBNP = 0 mm Hg. 4) To minimize step-discontinuities (2) between the
first and last R-R intervals of the 128-point data sets, more R-R
intervals were acquired from the recovery vs. basal stage, thus allowing
the heart rate to equilibrate towards its basal level.
A sufficient number (i.e. 128) of matched R-R intervals was not
available in all subjects for certain runs. Therefore, data from only
some of the subjects could be utilized for spectral analysis.
Computer Analysis
R-R intervals were digitized by an independent observer using a
Tales X-Y digitizer interfaced to a Tektronix 4052A computer. Fast
Fourier Transform (FFT) analysis was performed on each 128 R-R interval
data set using a standard (Cooley-Tukey) algorithm. The
root-mean-square (RMS) value for each data set was computed for the band
width encompassing the 2 through 64 harmonics. The RMS value is a
standard measurement most commonly used as an index of the effective
voltage of an electrical signal. In the present study, the RMS value is
used as an index of the "effective" interbeat interval spectral power
and is therefore measured in units of time.
Statistical Analysis
Students' t-test was used for paired-comparisons of RMS values,
digital heart rates and LBNP tolerance times. Values are expressed as
mean ± one standard deviation. Statistical significance is defined as P
value less than 0.05.
RESULTS
Spectral Analyses
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The results of the spectral analyses are given in Figs. 2-4. There
was no significant difference in spectral RMS values for subjects
pre-bedrest vs. bedrest while on placebo (93±33 ms vs. 84±38 ms; n=6
subjects). Similarly, for the comparison of placebo pre-bedrest vs.
placebo recovery there was no significant difference in RMS values:
91±31 ms vs 94±36 ms, respectively (n=7). However, when spectral RMS
was compared for subjects pre-bedrest vs. bedrest while on atropine
(63±24 ms vs. 40±23ms; n=7) a significant (p<.01) decrease was noted.
Furthermore, spectral RMS on atropine was significantly (p<.005) lower
than on placebo for subjects at bedrest (44±21 ms vs. 83±31 ms; n=6).
Representative plots of R-R interval time series and their
associated spectra in one subject during different interventions are
shown in Figs 5-7. Figure 5 compares pre-bedrest and bedrest runs while
on placebo. Both R-R interval plots (top panel) show comparable
variability and the power spectra (bottom panels) overlap for the entire
frequency range. Figure 6, in contrast, compares the atropine
pre-bedrest and atropine bedrest runs. The bedrest R-R interval plot
shows a visually apparent reduction in variability compared with
pre-bedrest (top panel). This is reflected in a reduction in spectral
power (bottom panel). Similarly (Figure 7), when the atropine bedrest
and placebo bedrest runs are compared, a marked reduction in R-R
interval variability with atropine is noted with an associated decrease
in spectral power.
Heart Rate Data
Resting heart rate (58.5±8.5 beats/minute) for all ten subjects on
placebo at bedrest was higher than pre-bedrest values (54.7±4.4
beats/minute). However this difference was not statistically
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significant. Resting heart rate, during the recovery period (59.118.9
beats/minute) was significantly (p<.05) higher than during the
pre-bedrest placebo period. The heart rate at bedrest with atropine
(83.7118.9 beats/minute), as significantly (P<.002) higher than atropine
pre-bedrest values (70.4112.A beats/minute), in addition to being
significantly (p<.01) higher than the placebo bedrest values given
above.
Orthostatic Tolerance Times
Orthostatic tolerance time for all ten subjects during the
pre-bedrest placebo phase (8061274 sec) was significantly (p<.05) higher
than during the bedrest placebo phase (5891314 sec), but not different
from placebo recovery phase (8111216 sec). Exercise tolerance times for
subjects in the atropine pre-bedrest phase (6581352 sec) were higher
than during the atropine bedrest phase (505±252 sec). However, this
difference was not statisticaly significant.
Discussion
This study demonstrates several findings of potential importance.
First, the data support the contention that bedrest impairs
cardiovascular reserve, evidenced by a reduction in heart rate
variability. Second, the unmasking of this effect by atropine suggests
the possible importance of the autonomic nervous system in mediating
this deconditioning effect. Furthermore, the study indicates the
utility of spectral analysis of cardiac interbeat interval dynamics as a
novel tool for assessing subtle perturbations in autonomic function and
in monitoring potentially pathologic alterations associated with
prolonged recumbency.
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Bedrest Deconditioning and Cardiovascular Control
Multiple studies (4,5,17,21,24) have suggested that prolonged
bedrest adversely affects cardiovascular performance. One finding which
appears to support this hypothesis is an increase in resting heart rate
usually observed after enforced recumbency in normal subjects (21,24).
In the present study, mean resting heart rate with bedrest was higher
than pre-bedrest. However the difference did not reach statistical
significance. Resting heart rate during the recovery phase was
significantly higher than during the pre-bedrest period, suggesting
that certain autonomic perturbations associated with bedrest persisted
for at least two weeks following return to sedentary activity in
previously well-trained individuals. The mechanism of the relative
tachycardia associated with bedrest has not been determined but could be
related to a decrease in vagal tone (or decreased sensitivity to vagal
stimulation), to an increase in sympathetic tone (or increased
sensitivity to sympathetic stimulation), or to some combination of these
effects.
While the influence of bedrest on vagal function has not been
directly studied, data from both animal (15) and human (5,16)
investigations suggested variable alterations in sympathetic function.
Krupina et al (15), for example, studied rabbits which had been
immobilized for up to six weeks and reported a reduction in
catecholamine content in the adrenal gland as well as the hypothalamus.
Chobanian et al. (5) compared catecholamine metabolism in six healthy
men before and during two to three weeks of bedrest. No changes in
pulse rate or blood pressure were noted in response to graded infusion
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of norepinephrine following bedrest. While not statistically
significant, there was a trend for serum catecholamine levels to
decrease in the supine state following bedrest, but to become increased
over control levels during tilt testing. This finding suggests an
instability in sympathetic control associated with bedrest. In our
study, subjects given atropine had significantly higher mean resting
heart rates at bedrest vs. pre-bedrest. This observation is consistent
with enhanced sympathetic or with decreased parasytnpathetic effects with
bedrest. A reduction in parasympathetic tone with enforced recumbency
would complement the well established link between increased vagal tone
and resting bradycardia in subjects who undergo exercise conditioning
(6,8,19).
In addition to its effort on resting heart rate, bedrest appears to
alter two other important indices of cardiovascular reserve: exercise
capacity and orthostatic tolerance. While prolonged bedrest appears to
reduce exercise capacity (3,4,21), the mechanisms underlying this
deleterious effect remain obscure. In particular, it is not certain
whether this deconditioning primarily reflects peripheral or central
factors, or some combination. Basal cardiac output does not appear to
be markedly altered following bedrest (5,20,24). However, Chobanian et
al. (5) noted a significant decrease in cardiac output during tilt
testing as compared to bedrest levels. This reduction in cardiac output
may be related at least in part to a decrease in blood volume, a
consistent finding after prolonged bedrest (5,17,20,21). Chobanian et
al. (5) also reported that peripheral vascular resistance during passive
tilt was higher for subjects at bedrest vs. control state. However,
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supine peripheral vascular resistance was not altered by bedrest. The
effect of bedrest on inotropic state has not been determined.
Bedrest and Heart Rate Variability
In this study, we investigated another parameter of cardiovascular
function, namely heart rate variability. While the normal cardiac
rhythm is referred to as "regular" sinus rhythm, interbeat intervals in
active healthy subjects show a wide range of variability. These
physiologic fluctuations which are important in normal homeostatic
regulation are "fine-tuned" by the interaction of the parasympathetic
and sympathetic branches of the autonomic nervous system (19). This
variability in heart rate includes more than just respiratory (phasic)
fluctuations. On the other hand, these fluctuations are not completely
random. Spectral analysis of R-R intervals recorded over multiple hours
in healthy subjects reveals a broadband frequency spectrum with
so-called "1/f scaling" (14). The term 1/f refers to spectra showing an
inverse relationship between frequency (f) and power (9,10). Thus in
1/f-like spectra, lower frequencies (harmonics) will show higher power
than the higher frequencies. The power spectra shown in figures 4-6 .are
1/f-like, with an inverse relationship between harmonics and power.
Loss of physiologic heart rate variability may be seen in a variety
of settings including aging (25), placental insufficiency syndromes
(13), diabetes mellitus and multiple sclerosis (18). We postulated that
prolonged bedrest might cause a similar reduction in heart rate
variability associated with autonomic deconditioning. The results of
the present study are consistent with this hypothesis. Of particular
interest was the observation that the deconditioning effects of bedrest
on R-R interval variability were relatively subtle and only apparent
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after atropine administration. No significant difference was noted in
spectral RMS values pre-bedrest vs. bedrest, although there was a trend
for the values to be lower in the bedrest phase. However, with
atropine, spectral RMS values at bedrest were significantly diminished
compared to pre-bedrest levels. This finding suggests that the normal
control mechanisms regulating heart rate variability are reduced with
prolonged bedrest and that additional interference with parasympathetic
function, in this case with atropine, induces an even more marked
reduction in normal R-R interval fluctuations.
The elevated resting heart rate noted after prolonged bedrest
(21,24) also suggests reduced parasympathetic tone. Pharmacological
doses of atropine in this setting are, therefore, likely to "relegate"
control of heart rate variability to the sympathetic system. The
decrease in cardiac interbeat interval variability in atropinized
subjects at bedrest vs. pre-bedrest suggests that sympathetic function
is also impaired with bedrest. The precise mechanisms of this
impairment are not known (5,15,16).
Spectral Analysis
The detection of alterations in interbeat interval dynamics with
spectral analysis supports the sensitivity of this technique. Up to the
present, spectral analysis of heart rate variability has had
surprisingly little application in clinical studies. Recently, time
series analysis has been used to characterize the pathologic low
frequency fluctuations in R-R intervals noted in patients with heart
failure, associated with the Cheyne-Stokes breathing (9). Gordon et al.
(11) recently reported abnormalities in short term fluctuations in heart
rate and respiration in the sudden infant death syndrome. In previous
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studies (1,22), frequency analysis was used to - define physiological
oscillations in interbeat intervals associated with respiration,
thermoregulation and baroreceptor control. Akselrod et al. (1) in
canine studies demonstrated the utility of power spectrum analysis as a
"probe" of cardiovascular control mechanisms. They observed a marked
decrease in spectral amplitude after parasympathetic blockade and
further reduction after total autonomic blockade. The present study
confirms the loss of spectral power associated with atropine
administration, as shown in figure 7.
The sensitivity of spectral analysis in this study is further
supported by its use in detecting the effect of bedrest on R-R interval
variability. The use spectral analysis, therefore, may complement
traditional ways of assessing cardiovascular function and monitoring
deconditioning effects, such as exercise and orthostatic tolerance
testing. In the present study, orthostatic tolerance time pre-bedrest
vs. bedrest was not significantly reduced in atropinized subjects at a
time when spectral analysis revealed a significant reduction in
interbeat interval variability. In contrast, mean orthostatic tolerance
time was reduced by 27% (p<.05) in subjects on placebo at bedrest
compared to pre-bedrest at a time when no significant difference was
apparent in spectral power or in the mean resting heart rate. The
reason for the apparent differential sensitivity of spectral analysis
and orthostatic tolerance testing is not clear. However, the data do
support the complementarity of these two indices in assessing
cardiovascular reserve.
Spectral analysis is particularly attractive because it provides a
quantitative tool for measuring physiological variability. The utility
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of this type of analysis is suggested in the following hypothetical
examples. Consider two data (e.g.interbeat interval) sets with
identical or nearly identical means (X. = X_) but very different
variances. In one case the variance is almost nil, while in the other
it is very marked. Whereas t-testing would reveal no significant
difference (X. - X_ = 0) the spectral power of the sample with greater
variability would be higher. Spectral analysis would also provide a way
of comparing two time series with identical means and identical
variances, since the data sets could comprise very different frequency
components depending on the ordering of the data points.
Despite its potential utility, spectral analysis of clinical data
is fraught with pitfalls. First, an adequate number of data points must
be available. We selected 128 R-R intervals per run to provide a
reasonable range of frequencies, i.e. up to the 64 harmonic. A
greater number of data points would have provided additional information
about higher frequency components, but were not available in this
retrospective analysis. In addition, since these 128 point data sets
were comprised of samples from serial stages of the LBNP protocol, equal
numbers of R-R intervals from matched stages of the LBNP protocol were
required for intra-subject comparisons. Another potential pitfall
relates to the selection of the first and last sample points, because a
marked discrepancy (step-discontinuity) between these points can
artifactually alter the frequency spectrum (2). We minimized such step
discontinuities by taking a greater number of beats from the final
(recovery) vs initial (basal) stage, thus allowing time for the heart
rate to equilibrate towards its control level (Figs 5-7).
Future Applications
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A more complete characterization of the role of the autonomic
nervous system in bedrest deconditioning would have been provided by
other interventions, including beta-blocking agents and vagotonic drugs
(eg. phenylephrine). Unfortunately, data from these interventions could
not be utilized in this retrospective study because there were too few
matched runs with adequate numbers of data samples for spectral
analysis. Future prospective studies with longer acquisition times per
LBNP stage should help in further assessing the role of autonomic
perturbations in bedrest deconditioning.
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FIGURE LEGENDS
Figure 1. Lower body negative pressure (LBNP) protocol used in study is
depicted graphically. See text for details.
Figure 2. Comparison of spectral root-mean-square (RMS) values for
subjects on placebo during pre-bedrest (PRE-BR), bedrest (BR) and
recovery (REG) phases of protocol.
Figure 3. Comparison of spectral root-mean-square (RMS) values for
subjects pre-bedrest (PRE-BR) and at bedrest (BR) after atropine.
Figure 4. Comparison of spectral root-mean-square (RMS) values for
subjects at bedrest while on placebo and atropine.
Figure 5. Representative interbeat interval plots (top panel) and
associated power spectra (bottom panel) from subject during placebo
pre-bedrest and placebo bedrest phases of protocol. dB = decibels. RMS
= root-mean-square value in milliseconds.
Figure 6. Representative interbeat interval plots (top panel) and
associate power spectra (bottom panel) from subject during atropine
pre-bedrest and atropine bedrest phases of protocol. Abbreviations as
in Fig. 5.
Figure 7. Representative interbeat interval plots (top panel) and
associated power spectrum (bottom panel) from subject during placebo
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bedrest and atropine bedrest phases of protocol. Abbreviations as in
Fig. 5.
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Atropine Bedrest vs. Placebo Bedrest
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